Durvalumab and Chemoradiotherapy Show No Survival Benefit in NSCLC
New research presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer has revealed that the combination of durvalumab (Imfinzi) and chemoradiotherapy does…